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Abstract
The tumor suppressor protein p53 has been described ‘‘as the guardian of the genome’’ for its crucial role in regulating the
transcription of numerous genes responsible for cells cycle arrest, senescence, or apoptosis in response to various stress
signals. Although p53 promotes longevity by decreasing the risk of cancer through activation of apoptosis or cellular
senescence, several findings suggest that an increase of its activity may have deleterious effects leading to selected aspects
of the aging phenotype and neurodegenerative diseases. There is the link between p53 and oxidative stress, the latter a
crucial factor that contributes to neurodegenerative processes like Alzheimer disease (AD). In the present study, using a
proteomics approach, we analyzed the impact of lack of p53 on the expression of several brain mitochondrial proteins
involved in different pathways, and how lack of p53 may present a target to restore neuronal impairments. Our
investigation on isolated brain mitochondria from p53(2/2) mice also provides a better understanding of the p53-
mitochondria relationship and its involvement in the development of many diseases.
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Introduction
The p53 tumor suppressor protein plays a central role to
preserve genomic integrity [1] with effect on cell fate [2]. p53 is
involved in many cellular pathways, and when this protein
becomes activated in response to stress signals [3] it can promote a
transient cell cycle arrest, cell death (apoptosis) or permanent cell
cycle arrest (senescence) [4]. p53 often is lost or mutated in cancers
[5]. Both apoptosis and cellular senescence prevent the propaga-
tion of damaged DNA [6] with consequent reduction of the risk of
cancer. However, both of these processes favor tissue atrophy and
aging phenotype [7]. Therefore, p53 can exert both beneficial and
deleterious effects depending on a delicate balance between tumor
suppressor and longevity.
The interaction among p53 and oxidative stress is intriguing,
since this latter is well known to be associated with several age-
related diseases [8,9]. Under normal conditions, p53 protein levels
are low and regulated by IKK but prominently by Mdm2, an
ubiquitin ligase responsible for p53 degradation. Cellular stress
reduces the interaction between p53 and Mdm2 leading to
accumulation of the former [10], and several reactive oxygen
(ROS) and nitrogen species (RNS) also modify p53 and its activity
[11]. Moreover, the activation of p53 leads to the generation of
ROS as well [12,13]. Thus, there is an intricate link between p53
and ROS, even though specific mechanisms of their interplay are
still unclear. Several results show that cellular redox status is under
control of p53, and p53 may exert opposite effects in ROS
regulation depending on its levels [11]. Physiological levels of p53
maintain ROS at basal levels through transactivation of antiox-
idant genes such as SESN1 (mammalian sestrin homologue),
SESN2, and glutathione peroxidase-1 (GPx1) [14]. In addition,
constitutive levels of p53 link energy metabolism to ROS
formation by regulating the expression of essential metabolic
enzymes that are able to balance energy metabolism among
mitochondrial respiration, glycolysis, and the pentose phosphate
shunt [11], and mitochondrial respiration is a major source of
ROS [15,16].
High levels of p53 increase intracellular ROS by transactivation
of genes encoding pro-oxidant proteins such as NQO1 (quinone
oxidoreductase) [11] and proline oxidase (POX) [11], and for pro-
apoptotic proteins, which include BAX and PUMA [11]. Further,
the repression of antioxidant enzymes such as MnSOD by p53, is
another means to increase intracellular ROS [11,17].
Changes in mitochondrial ROS production may influence the
p53 pathway [18,19]. Also p53 can regulate ROS production in
mitochondria [20]. This suggests that there is an interaction
between mitochondria and p53 essential to allow normal cellular
functions and its interruption may have severe consequences [21].
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Consequently, understanding better the mechanisms underlying
this interaction may be helpful to further comprehend the
development and the progression of many diseases [21].
The aim of this study was to analyze the impact that the lack of
p53 had on basal protein expression levels in mitochondria
isolated from mice brain, to gain insight into the special link
between p53 and oxidative stress, and its impact on neurodegen-
erative disorders, such as Alzheimer disease. A proteomics
approach was used.
Materials and Methods
Chemicals
All chemicals used in this study were purchased from Bio-Rad
(Hercules, CA).
Animals
Heterozygous mice p53(2/+) were maintained in our laboratory
to generate p53(2/2) and wt littermates. p53(2/2) are in the
C57BL/6 background and were initially produced in the
laboratory of Dr. Tyler Jacks at the Center for Cancer Research
and Department of Biology, Massachusetts Institute of Tecnology
(Cambridge, MA). The targeted disrupted p53 genes do not yield
p53 protein, because of 40% of their gene-coding region is
eliminated by the induced mutation. Male mice with an age
between 10 and 12 weeks old were used in our study. All animal
experimental procedures were approved by the Institute Animal
Care and Use Committe of the University of Kentucky and
followed NIH Guidelines for the Care and Use of Laboratory
Animals.
Sample preparation
Mice were humanely euthanized, and the brain was quickly
removed. Mitochondria were promptly isolated from the brain by
differential centrifugation methods using Percoll Gradientswith
some modifications [22].
Isoelectric focusing (IEF)
Proteins from mitochondrial homogenates (200 mg) were
precipitated by addition of ice-cold 100% trichloroacetic acid
(TCA) (15% final concentration) and incubated on ice for 10 min.
Samples were centrifuged at 14,000 rpm (23,7006g) for 5 min at
4uC. Pellets were washed three times with 0.5 mL of wash buffer
[1:1 (v/v) ethanol: ethyl acetate] to remove excess salts. After the
final wash, pellets were dried at room temperature (RT) for
,10 min and rehydrated for 2 h at RT in 200 ml of a rehydration
buffer [8 M urea, 2 M thiourea, 50 mM DTT, 2.0% (w/v)
CHAPS, 0.2% Biolytes, Bromophenol Blue], placed in agitation
for 3 hours, and then sonicated for 10 s. Samples (200 mg) were
applied to 11 cm pH 3–10 ReadyStripTM IPG strips and after 2 h,
2 ml of mineral oil was added to prevent sample evaporation.
Strips were actively rehydrated at 20uC for 18 h at 50 V, focused
at a constant temperature of 20uC beginning at 300 V for 2 h,
500 V for 2 h, 1000 V for 2 h, 8000 V for 8 h, and finishing at
8000 V for 10 h rapidly. IPG strips were stored at 280uC until the
second dimension of analysis was carried out.
Figure 1. Proteomic analysis of differential protein expression (WT vs. p53KO). Proteomic profile of representative 2D-gels with proteins
differently expressed between mitochondrial fraction isolated from the brain of WT mice and p53(2/2) (left); expanded images of protein spots that
have significantly different levels (p,0.05) between WT and p53(2/2) (right).
doi:10.1371/journal.pone.0049846.g001
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Two-dimensional polyacrylamide gel electrophoresis
(2D-PAGE)
2D-PAGE was performed to separate proteins on IEF strips
based on molecular migration rate. IEF strips were thawed and
equilibrated for 10 min in equilibration buffer A [50 mM Tris–
HCl, pH 6.8, 6 M urea, 1% (w/v) SDS, 30% v/v glycerol, 0.5%
DTT] and then re-equilibrated for 10 min in equilibration buffer
B [50 mM Tris–HCl, pH 6.8, 6 M urea, 1% (w/v) SDS, 30% v/v
glycerol, 4.5% IA]. Criterion precast linear gradient (8–16%)
Tris–HCl polyacrylamide gels were uesd to perform second
dimension electrophoresis. Precision Plus ProteinTM All Blue
Standards and samples were run at a constant voltage of 200 V for
65 min.
SYPRO RubyH staining
After 2D-PAGE, gels were incubated in a fixing solution [7%
(v/v) acetic acid, 10% (v/v) methanol] for 20 min at RT. Sypro
RubyH Protein Gel Stain (,50 ml) was added to gels to stain them
overnight at RT on a gently rocking platform. Gels then were
placed in deionized water at RT until scanning. Gels were scanned
into Adobe Photoshop 6.0 with a Molecular Dynamics STORM
Phosphoimager (lex/lem: 470/618 nm) and stored in deionized
water at 4 uC until further use.
Image Analysis
Differential expression. Spot intensities from SYPRO Ru-
byH-stained 2D-gel images of WT and p53(2/2) samples were
quantified by densitometry according to the total spot density
using PD Quest analysis software from Bio-Rad (Hercules, CA).
Table 1. Proteins Expressed Differently in Mitochondrial Fraction Isolated from the Brain of WT and p53(2/2) mice.
Spot Protein Identified
Accession
# Coverage
Number of
identified
peptidesa Score
MW
(kDa) pI P valueb Foldc
1 Guanine nucleotide-binding
protein G (o) subunit alpha
P18872 12.15 3 24.11 40.1 5.53 0.0019 212 q p53KO
2 ATP synthase subunit beta,
mitochondrial
P56480 4.54 2 18.16 56.3 5.34 0.0035 125 q p53KO
3 Heat shock cognate 71
kDa protein
P63017 37.31 20 196.60 70.8 5.52 0.002 212 q p53KO
4 Aldehyde dehydrogenase
family 5, subfamily A1
B2RS41 14.72 6 36.70 55.9 8.25 0.0009 131 q p53KO
5 Glutamate dehydrogenase
1, mitochondrial
P26443 26.34 13 78.69 61.3 8.00 0.0076 131 q p53KO
6 Isoform mithocondrial
of Fumarate hydratase
P97807-2 25.57 8 62.73 50.0 7.94 0.0019 325 q p53KO
7 Acetyl-CoA acetyltransferase Q8QZT1 26.89 8 50.64 44.8 8.51 0.00079 166 q 53KO
8 Isoform Mt-VDAC1 of Voltage-
dependent anion-selective
channel protein 1
Q60932-2 38.16 7 74.55 30.7 8.54 0.0027 201 q p53KO
9 Aspartate aminotransferase P05202 43.72 17 174.33 47.4 9.00 0.0037 210 q p53KO
10 Mn Superoxide dismutase P09671 13.96 4 43.39 24.6 8.62 0.0026 133 q 53KO
11 Cytochrome b-c1
complex Rieske subunit
Q9CR68 26.28 7 70.31 29.3 8.70 0.0030 252 q 53KO
12 Thioredoxin-dependent
peroxide reductase
P20108 28.40 7 41.17 28.1 7.58 0.0015 253 q 53KO
aThe number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides.
bThe fold-change in spot density from p53(2/2) mice compared to wt. The arrow indicates the direction of change.
cThe p-value associated with fold-change calculated using a Student’s t-test.
doi:10.1371/journal.pone.0049846.t001
Table 2. Functionalities of Identified Proteins Differently Expressed.
Functions Proteins involved
Energy or mitochondrial alterations ATP synthase subunit beta, mitochondrial Aldehyde dehydrogenase family 5, subfamily A1
Glutamate dehydrogenase 1, mitochondrial Isoform mitochondrial of Fumarate hydratase Acetyl-
CoA acetyltransferase VDAC1 of Voltage-dependent anion-selective channel protein 1 Aspartate
aminotransferase Mn Superoxide dismutase Cytochrome b-c1 complex Rieske subunit
Signal transduction Guanine nucleotide-binding protein G (o) subunit alpha
Antioxidant defence/detoxification dysfunction Mn Superoxide dismutase Thioredoxin-dependent peroxide reductase
Chaperone proteins Heat shock cognate 71 kDa protein
doi:10.1371/journal.pone.0049846.t002
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Intensities were normalized to total gel densities and/or densities
of all valid spots on the gels. Only spots with a 1.5-fold increase or
decrease in normalized spot density in those samples and a
statistically significant difference based on a Student’s t-test at 95%
confidence (i.e., p,0.05) were considered for MS/MS analysis.
In-gel trypsin digestion
In-gel trypsin digestion of selected gel spots was performed as
previously described [23]. Briefly, protein spots identified as
significantly altered were excised from 2D-gels with a clean,
sterilized blade and transferred to Eppendorf microcentrifuge
tubes. Gel plugs were then washed with 0.1 M ammonium
bicarbonate NH4HCO3) at RT for 15 min, followed by incuba-
tion with 100% acetonitrile at RT for 15 min. After solvent
removal, gel plugs were dried in their respective tubes under a flow
hood at RT. Plugs were incubated for 45 min in 20 ml of 20 mM
DTT in 0.1 M NH4HCO3 at 56uC. The DTT/NH4HCO3
solution was then removed and replaced with 20 ml of 55 mM
iodoacetate (IA) solution in 0.1 M NH4HCO3 and incubated with
gentle agitation at room temperature in the dark for 30 min.
Excess IA solution was removed and plugs incubated for 15 min
with 200 ml of 50 mM NH4HCO3 at RT. A volume of 200 ml of
100% acetonitrile was added to this solution and incubated for
15 min at room temperature. Solvent was removed and gel plugs
were allowed to dry for 30 min at RT under a flow hood. Plugs
were rehydrated with 20 ng/ml of modified trypsin (Promega,
Madison, WI, USA) in 50 mM NH4HCO3 in a shaking incubator
overnight at 37uC. Enough trypsin solution was added in order to
completely submerge the gel plugs.
Mass spectrometry (MS)
Salts and contaminants were removed from tryptic peptide
solutions using C18 ZipTips (Sigma-Aldrich, St. Louis, MO,
USA), reconstituted to a volume of ,15 ml in a 50:50 water:
acetonitrile solution containing 0.1% formic acid. Tryptic peptides
were analyzed with an automated Nanomate electrospray
ionization (ESI) [Advion Biosciences, Ithaca, NY, USA] Orbitrap
XL MS (Thermo-Scientific, Waltham, MA, USA) platform. The
Orbitrap MS was operated in a data-dependent mode whereby
the eight most intense parent ions measured in the Fourier
Transform (FT) at 60,000 resolution were selected for ion trap
fragmentation with the following conditions: injection time 50 ms,
35% collision energy, MS/MS spectra were measured in the FT at
7500 resolution, and dynamic exclusion was set for 120 s. Each
sample was acquired for a total of ,2.5 min. MS/MS spectra
were searched against the International Protein Index (IPI)
database using SEQUEST with the following parameters: two
trypsin miscleavages, fixed carbamidomethyl modification, vari-
able methionine oxidation, parent tolerance 10 ppm, and
fragment tolerance of 25 mmu or 0.01 Da. Results were filtered
with the following criteria: Xcorr1.5, 2.0, 2.5, 3.0 for 1, 2, 3, and 4
charge states, respectively, Delta CN0.1, and P-value (protein and
peptide) 0.01. IPI accession numbers were cross-correlated with
Swiss Prot accession numbers for final protein identification.
Statistical analysis
All statistical analyses were performed using a Mann-Whitney U
statistical test and a two-tailed Student’s t-test. p,0,05 was
considered significant for differential fold-change values. Only
proteins with significant p-values from both tests were considered
further for MS identification. Protein and peptide identifications
obtained with the SEQUEST search algorithm with p,0.01 were
considered statistically significant. To further validate SEQUEST
identification, the location of protein spots (i.e., molecular weight
[MW] and isoelectric point [pI]) on 2D-gels was manually checked
based on expected MW and pI values from SwissProt database
information.
Results
Proteomics
Proteomics analysis using 2-DE and Sypro Ruby staining was
performed on proteins isolated from brain mitochondria of WT
and p53(2/2) mice to determine proteins differently expressed.
Fig. 1 shows 2D-gel images related to these analyses, with
expanded images of protein spots significantly different (p,0.05)
between WT and p53(2/2). Twelve proteins were identified as
differently expressed between WT and p53(2/2) mice, and
interestingly all twelve of these proteins were significantly over-
expressed in p53(2/2) samples. Surprisingly, we did not find any
mitochondrial proteins down-regulated in p53(2/2) mice relative
to WT. The protein spots of interest were excised from the gels,
and following digestion with the trypsin peptide were subjected to
MS/MS analyses. Proteins identified are listed in Table 1 with the
number of peptide sequences, the score, the coverage, MW, pI,
fold-change levels, and p-value. All protein identifications were
consistent with comparison of protein positions on the gel with
MW and pI from databases.
Figure 2. Putative network of pathways regulated by p53KO. A model of how the lack of p53 affects biological pathways that would
attenuate progression of neurodegenerative disorders. Our result potentially makes p53 a novel therapeutic target for the delay, treatment, or
prevention of these diseases.
doi:10.1371/journal.pone.0049846.g002
Proteomics of p53-Regulated Pathways in Brain
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The identified proteins were: guanine nucleotide-binding
protein G (o) subunit alpha (212-fold qp53KO, *P,0.0019),
ATP synthase subunit beta (125-fold qp53KO, *P,0.0035), heat
shock cognate 71 (212-fold qp53KO, *P,0.002), aldehyde
dehydrogenase family 5, subfamily A1 (131-fold qp53KO,
*P,0.0009), glutamate dehydrogenase 1 (131-fold qp53KO,
*P,0.0076), mitochondrial isoform of fumarate hydratase (325-
fold qp53KO, *P,0.0019), acetyl-CoA acetyltransferase (166-
fold qp53KO, *P,0.00079), isoform Mt-VDAC1 of voltage-
dependent anion-selective channel protein 1 (201-fold qp53KO,
*P,0.0027), aspartate aminotransferase (210-fold qp53KO,
*P,0.0037), Mn superoxide dismutase (133-fold qp53KO,
*P,0.0026), cytochrome b-c1 complex Rieske subunit (252-fold
qp53KO, *P,0.0030), and thioredoxin-dependent peroxide
reductase (253-fold qp53KO, *P,0.0015).
Discussion
Several studies have described p53, an important tumor
suppressor protein, as the guardian of the genome [1,2] for its
critical role in regulating the transcription of numerous genes
responsible for cells cycle arrest, senescence, or apoptosis in
response to various stress signals [4]. Therefore, p53 is crucial in
maintaining genetic stability [1]. What determines cell fate is
unclear but different factors including the cell type, the particular
insult, and the severity of damage are involved in this decision
[24].
Undoubtedly p53 promotes longevity by decreasing the risk of
cancer through activation of apoptosis or cellular senescence, but
several reports suggest that an increase of its activity may have
detrimental effects leading to selected aspects of the aging
phenotype [7,25] and neurodegenerative disease. Thus, there is
a balance between cell death and survival that under normal
conditions optimizes tumor suppression without accelerating
aging.
Previous research from our laboratory found p53 over-
expressed and oxidatively modified by oxidative and nitrosative
stress in brain from subjects with mild cognitive impairment (MCI)
and AD brain, compared to control samples [26,27]. Conforma-
tional alterations of p53 in MCI and AD are known [19]. These
observations are consistent with the role played by p53 in neuronal
death detected in neurodegenerative conditions, and with an
important link of p53 with oxidative stress. ROS and p53 appear
to be interconnected at multiple levels in their signaling pathways.
First, ROS are potent activators of p53, acting in different ways
such as damaged DNA, and even by regulating the redox status of
cysteines present in the DNA-binding domain of p53, affecting its
DNA-binding activity [26,28,29]. Moreover, once activated p53
generates downstream ROS which mediate apoptosis [12,30].
Therefore p53 appears to regulate cellular redox status [11].
Since oxidative stress has been considered a crucial factor that
contributes to neurodegenerative processes like AD [31–33], p53
could be a therapeutic target to reduce the levels of ROS, and in
this way prevent or attenuate neuronal death in neurodegenerative
disorders such as MCI and AD.
In a previous study, we demonstrated for the first time that the
lack of p53 significantly decreases basal levels of oxidative and
nitrosative stress in mice brain, and that this loss of p53 could
activate diverse protective pathways involved in maintaining
cellular homeostasis in the brain of p53(2/2) mice [20]. In the
present study using proteomics, we gained insight into the role of
p53 in the CNS, and tested the hypothesis that knock out of p53
affected the expression of several brain mitochondrial proteins
involved in different pathways; thus, loss of p53 may present a
target to restore neuronal impairment. Since our investigation was
performed on isolated brain mitochondria from p53(2/2) mice,
our results conceivably could provide insights into progression of
many mitochondrial-associated diseases. Hence, the identified
proteins are involved in energy and mitochondrial alterations,
signal transduction, antioxidant defense, and chaperone proteins,
as shown in Table 2.
Antioxidant defense
Interestingly, MnSOD was significantly increased in mitochon-
dria isolated from the brain of p53(2/2) mice compared to WT.
This data was already shown in our prior study [20] and are
consistent with the notion that MnSOD is transcriptionally
repressed by p53 [34,35] with consequent propagation of oxidative
stress, since MnSOD provides critical antioxidant defense.
Because the apoptotic programs require oxidative stress for their
execution, an overexpression of MnSOD was shown to increase
resistance to p53-dependent apoptosis [17,34]. Drane et al. [34],
and St. Clair and colleagues [18], further demonstrated that
MnSOD has a mutual activity on p53 reducing its expression, and
even negatively modulating its apoptotic function. Several studies
indicate that overexpression of MnSOD protects neurons from
oxidative damage thus exerting a defensive role during AD
development [36]. St. Clair and co-workers [36], using APP-PS-1
neurons as a model of AD, found a reduction of MnSOD
expression during neuronal maturation with high levels of
oxidative stress. These researchers also indicated p53 as a possible
factor for the suppression of MnSOD [36]. Therefore, an
overexpression of MnSOD through the inhibition of p53 could
be helpful to prevent or slow the progression of neurodegenerative
processes such as AD.
Thioredoxin-dependent peroxide reductase, also called perox-
iredoxin 3, is an antioxidant protein localized mainly in the matrix
of mitochondria, and it regulates physiological levels of H2O2 [37].
The peroxiredoxin system requires a family of proteins called
sestrins for its regeneration [38], and sestrin expression is regulated
by p53 [39,40]. Previous studies showed that p53 upregulates the
expression of sestrins, including peroxiredoxin [14]. In contrast, in
our study, we found an increase of Prdx3 levels in the
mitochondrial of p53(2/2) mice, and a plausible explanation of
this result could be, as proposed in our previous work [20], that the
lack of p53 could disturb cellular homeostasis causing the
activation of protective pathways by cells to combat cellular
damage. Since H2O2 plays a central role in induction of apoptosis
[41], the reduction of mitochondrial levels of H2O2by overex-
pression of Prdx3 seems to be antiapoptotic [42], and therefore
beneficial for preserving cell survival. In addition Prdx3 was
previously found down-regulated in AD brain [43].
Chaperone proteins
Heat shock cognate (HSC)-71, a member of the Hsp70 family of
proteins [44], was found up-regulated in the mitochondrial
fraction isolated from the brain of p53(2/2) mice compared to
WT. Previously, Agoff [45] established that Hsp70 is repressed by
p53, corroborating our result.
The Hsp family acts as chaperones assuring proper folding and
assembly of proteins, and protects cells against apoptosis [46]. This
latter function is prominently carried out by Hsp70. It is
conceivable that the Hsp family exerts a crucial role in neuronal
death linked with neurodegenerative disorders. HSC-71 is the
constitutive isoform of the Hsp 70, activated by cells in adverse
conditions. This chaperone protein is involved in the degradation
of damaged proteins shuttling them for proteolysis [47]. In AD,
the expression of Hsps seems to have a protective function to
Proteomics of p53-Regulated Pathways in Brain
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prevent the formation of amyloid fibrils [48], and previously,
HSC-71 was found down regulated [49], and oxidatively modified
in AD brain [50]. Therefore the increase of HSC-71 expression
levels, induced by the lack of p53, conceivably could play a
protective role in AD progression.
Energy dysfunction and mitochondrial alterations
Several findings suggest that p53 has a role in the regulation of
pathways involved in glucose metabolism, supporting oxidative
phosphorylation and the pentose phosphate shunt, and inhibiting
glycolysis [11]. These activities of p53 prevent cancer develop-
ment. In addition, mitochondria are a major site in which some
constituents of these pathways play a role. Therefore, there is a
connection between p53 and mitochondria [51], and a better
understanding of this link conceivably could provide insight into
the progression of mitochondria related disorders.
In our study VDAC was found up-regulated in mitochondria of
p53(2/2) mice compared to mitochondria from WT mice. VDAC
is a component of the mitochondria permeability transition pore
(MPT), which allows the exchange of metabolities like ATP in and
out of mitochondria, and it is also involved in synaptic
communication and in the early phases of apoptosis [52]. Previous
studies revealed the anti-apoptotic function of VDAC through its
ability to bind BAK, a pro-apoptotic protein [53]. Likewise,
VDAC may restrain p53, reducing its levels [54]. Therefore, these
prior results suggest that VDAC and p53 are interconnected, and
that lack of p53 could increase the expression of VDAC, in
according with our results. The upregulation of VDAC conceiv-
ably could improve synaptic transmission and cell survival as well
as modulate apoptotic events.
In addition, in our study we found several energy-related
proteins: ATP synthase subunit beta, mitochondrial isoform of
fumarate hydratase, and cytochrome bc1 complex Rieske subunit,
over-expressed in brain mitochondrial of p53(2/2) mice. Since
inhibition of p53 leads to dependence of cells on glycolysis and to
considerable impairment of aerobic pathways [55], our data may
reflect a stress response to compensate for this effect. Moreover the
p53-dependent protein targets may be highly cellular type specific.
Accordingly, our results also may reflect the high glycolytic
metabolism in brain. The over-expression of these proteins,
involved in energy metabolism, seems to confirm the hypothesis of
this work, in which diminution of p53 may represent a target to
restore mitochondrial dysfunction, since these proteins were found
altered in models of aging and neurodegenerative diseases [56–
58].
p53 plays an additional role in the regulation of glutamate
metabolism activating the expression of glutaminase 2 which
provides glutamate to promote the tricarboxylic acid (TCA) cycle
and oxidative phosphorylation [59]. Glutamate may be oxidatively
deaminated by glutamate dehydrogenase to form a-ketoglutarate,
which can then enter the Krebs cycle and be oxidized to CO2 and
H2O, or a-ketoglutarate can be transaminated by aspartate
aminotransferase to form the neurotransmitter glutamate. Both
of glutamate dehydrogenase and aspartate aminotransferase were
shown up-regulated in mitochondrial brain of p53 knockout mice.
These data are consistent with our previous results showing the
enhancement of aerobic pathways in p53-deficient mice [20], and
their contrast with the current literature [60] can be explained by
the notion that p53-dependent effects cannot be reproduced in a
particular cell system. Previously, glutamate dehydrogenase and
aspartate aminotransferase have been shown to be oxidatively
modified, and expressed differently in animal models of neurode-
generation [61–63]. Therefore, even these results strongly support
the concept that inhibition of p53 may attenuate neurodegener-
ative disorders.
Another notable mitochondrial protein found to be basally up-
regulated in brain mitochondria of p53(2/2) mice was aldehyde
dehydrogenase family 5, subfamily A1, a member of the aldehyde
dehydrogenase (ALDH) family known to participate in oxidizing a
plethora of endogenous and exogenous aldehydes [64]. Previous
studies showed a prominent role of ALDH family, including
ALDH1, ALDH2, ALDH3A, and ALDH5A, in the oxidation of
4-hydroxy-trans-2-nonenal (HNE) to 4-hydroxy-trans-2-nonenoate
(HNEAcid) [65,66], a major pathway of HNE detoxification. In
particular, in rat and in human brain, HNEAcid formation occurs
in the mitochondria by ALDH5A [65]. The detoxification of these
aldehydes is important for neurodegenerative disorders such as
AD, since high levels of unsaturated lipid content increase brain
vulnerability to oxidative damage [67]. Therefore up-regulation of
ALDH5 could be protective against cell damage. Previous
research identified ALDH4 as a p53-inducible gene [68]. The
current study is the first to show that the lack of p53 increases
ALDH5 expression levels, adding an additional p53-target gene.
An increasing body of evidence places p53 as a member of an
intriguing network that includes tumor suppression and aging [69].
The tumor suppressor activity of p53 protects against malignant
transformation but also enhances the aging process [69]. As the
role of p53 in aging is still unclear, we designed this study gain
insights into the role of p53 in the brain and its involvement in
neuronal cell death.
In conclusion, we identified brain mitochondrial proteins in p53
null mice that display crucial p53-dependent cellular functions in
the central nervous system. Therefore, our results reinforce the
concept that the lack of p53 could disturb cell homeostasis causing
cells to stimulate defensive pathways. We also elaborated on the
link between p53 and mitochondria as we used for the study
mitochondria from p53 knock out mice. Since mitochondrial
dysfunction is a key feature of neurodegenerative diseases such as
AD, p53 conceivably could be a novel therapeutic target for the
treatment of these disorders (Fig. 2).
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